The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: the microparticle-associated immune complexes

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

| Citation          | Cloutier, Nathalie, Sisareuth Tan, Luc H Boudreau, Catriona Cramb, Roopashree Subbaiah, Lauren Lahey, Alexandra Albert, et al. 2013. The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: the microparticle-associated immune complexes. EMBO Molecular Medicine 5(2): 235-249. |
|-------------------|----------------------------------------------------------------------------------------------------|
| Published Version | doi:10.1002/emmm.201201846                                                                         |
| Citable link      | http://nrs.harvard.edu/urn-3:HUL.InstRepos:11180390                                                |
| Terms of Use      | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: the microparticle-associated immune complexes

Nathalie Cloutier¹, Sisareuth Tan², Luc H. Boudreau¹, Catriona Cramb³, Roopashree Subbaiah⁴, Lauren Lahey³, Alexandra Albert¹, Ruslan Shanasyer⁵, Reuben Gobezie⁶, Peter A. Nigrovic⁵,⁷, Richard W. Farndale⁸, William H. Robinson³, Alain Brisson², David M. Lee⁵,⁹, Eric Boilard¹*

Keywords: arthritis; autoantigens; immune complexes; microparticles; platelets

DOI 10.1002/emmm.201201846

Received August 08, 2012
Revised October 17, 2012
Accepted November 05, 2012

INTRODUCTION

Upon activation, cells of many different lineages bud small extracellular vesicles called microparticles (MP) (also known as microvesicles or ectosomes) from the cytoplasmic membrane. Given the universality of this process, MPs likely play essential functions that include cell–cell communication and transportation of mediators (Beyer & Pisetsky, 2010; Distler et al, 2005b; Gyorgy et al, 2011b). It is increasingly appreciated that elevated levels of MPs are evident in diverse diseases (Beyer & Pisetsky, 2010; Distler et al, 2005b; Gyorgy et al, 2011b). Platelet MPs in particular were observed in autoimmune disorders including systemic lupus erythematosus (SLE; Pereira et al, 2006; Sellam et al, 2009), Sjögren’s syndrome (Sellam et al, 2009), multiple sclerosis (Sheremata et al, 2008), antiphospholipid syndrome (Jy et al, 2007), and RA (Boilard et al, 2010, 2012; Knijff-Dutmer et al, 2011b).
Immune complexes (IC) represent immunoglobulins and complement clustered about target antigen. They are extremely potent at eliciting inflammatory responses and implicated in response to infections as well as multiple autoimmune diseases such as Sjogren’s syndrome (Vouglas et al., 2010), SLE (Munoz et al., 2010), multiple sclerosis (Cross et al., 2001; Ziemssen & Ziemssen, 2005), antiphospholipid syndrome (Ruiz-Irastorza et al., 2010) and RA (Nigrovic, 2006). Given the simultaneous presence of ICs and MPs in autoimmune disorders, we examined MPs keeping in mind that they could themselves serve as antigenic surface for formation of functional ICs, referred to hereafter as microparticle ICs (mpICs).

Using high sensitivity flow cytometry (hs-FCM), transmission electron microscopy and proteomic approaches, we found that ICs in RA synovial fluid frequently include MPs, thereby forming true mpICs. Although we observed that MPs originating from platelets express FcγRIIa, mpICs formed not through binding to this receptor but rather by recognition of citrullinated autoantigens such as vimentin and fibrinogen. Together, these results identify a unique site of autoantigen expression in RA and suggest that MPs, including those derived from platelets, may participate in the generation of a novel type of potent ICs in this disease.

RESULTS

MPs in SF are highly heterogeneous in size
MPs are widely recognized as ~100–1000 nm extracellular vesicles that can exhibit phosphatidylserine. These uncommon features permit the detection of MPs cytofluorometrically by employing Annexin-V (which recognizes phosphatidylserine) conjugated to fluorochromes and size discrimination (Connor et al., 2010; Gyorgy et al., 2011a; Perez-Pujol et al., 2007; Thiagarajan & Tait, 1991). However, standard flow cytometry is not well adapted to the detection of such small MPs. The demonstration of the common biophysical properties of ICs and MPs (Gyorgy et al., 2011a) and the recent development of improved flow cytometry approaches for MP detection prompted us to further analyse MPs in RA.

After optimizing high sensitivity flow cytometry (hs-FCM) parameters to distinguish small particles (Fig 1A), we assessed size and quantity of MPs in RA. For comparison, the MPs present in psoriatic arthritis (PA) – a disease family not associated with intra-articular ICs and complement consumption – were also examined. Similarly to MPs, ICs can display dimensions ranging from 100 to 1000 nm (Gyorgy et al., 2011a). Further, since it is hypothesized that ICs can interact with multiple MPs to form larger components, we included all particles up to 3500 nm in diameter for our analyses. Interestingly, unlike MPs in PA SF, MPs in RA SF appear highly heterogeneous in size and include two major subpopulations, one exhibiting diameters ranging from ~100 to ~300 nm and a second one from ~700 to ~3000 nm (Fig 1B and C).

Given the common biophysical properties of ICs and MPs and the prominent quantities of ICs in SF (Gyorgy et al., 2011a), we utilized an established detergent lysis protocol to differentiate these entities (Gyorgy et al., 2011a). With this method, membrane phospholipids from MPs are solubilized by detergent while the ICs remain intact (Gyorgy et al., 2011a). We observe that the Annexin-V+ particles are promptly solubilized by Triton X-100 treatment, a finding consistent with the membrane composition present in MPs (Fig 1D). These analyses reveal 745,000 ± 171,000 Annexin-V+ MPs/µl in SF of RA patients (n = 23). For comparison, we find 193,000 ± 20,000 Annexin-V+ MPs/µl in SF of PA patients (n = 18), significantly lower than the concentrations detected in RA (p = 0.0004; Fig 1E). Interestingly, we observe that MPs in RA SF are not only more abundant than in PA SF, they also display different dimensions, suggesting that they are associated with other macromolecular structures.

MPs and ICs associate in SF from patients with RA, not PA

Intrigued by the presence of large dimension MPs in RA SF, we hypothesized that MPs could bind immunoglobulins and thereby form large MP-containing ICs (mpICs). To assess the presence of mpICs in RA SF, we used cryo-TEM, which allows direct visualization of small particles and their membrane bilayers. We further examined the exposure of phosphatidylserine in RA SF mpICs using Annexin-V conjugated to 4 nm gold nanoparticles and identified immunoglobulin containing ICs using larger gold nanoparticles (10 nm) conjugated to protein A. Using this method, we identify macromolecular structures up to 2 µm in diameter that contain both ICs and MPs (mpICs). Interestingly, these mpICs often harbour multiple MPs at the periphery (Fig 2A–C), ~65% of them expressing phosphatidylserine. Importantly, these observations were verified in freshly obtained RA SF (n = 5), ruling out the involvement of freezing–thawing in an artificial generation of mpICs.

Having visualized mpICs, we employed hs-FCM to analyse them (Fig 3A). We measure 39,400 ± 9400 mpICs/µl in RA SF (Fig 3B). The quantification of the ICs in these same fluids (Supporting Information Fig S1) reveals that the majority (62 ± 7%) of the detectable ICs are in fact mpICs (Fig 3C). These observations provide an explanation for the presence of two subpopulations of MPs evident in RA SF. Specifically larger particles (from ~700 to 3000 nm; upper inset in Fig 3A) contain mpICs. Conversely, the MPs not associated with IgG are characterized by smaller dimensions (100–300 nm; lower inset in Fig 3A) and represent the majority of the total Annexin-V+ MPs (93 ± 1.4; Supporting Information Fig S2). Interestingly, although MPs and IgG are both present in PA SF, only 2000 ± 900 mpICs/µl could be detected (Fig 3B and D).

Platelet-derived mpICs are present in RA SF

Having established the presence of mpICs in RA SF, we next investigated mechanisms by which ICs and MPs combine. A key question for further mechanistic investigation is identification of...
the cellular source(s) of MPs in SF. Considering their role in arthritis (Boilard et al., 2010, 2012), we queried whether platelet MPs contribute significantly to mpICs in RA SF. For these analyses, we assessed the presence of the platelet specific integrin CD41 in mpICs using hs-FCM. Consistent with the vast heterogeneity that prevails among RA patients, the amount of CD41⁺ mpICs in RA SF differs from one patient to another (n = 25; two examples shown on Fig 3E). Interestingly, the number of CD41⁺ mpICs in RA SF is significantly higher than those observed in PA SF (n = 18; p = 0.0006; Fig 3F). Importantly, although the ICs remain intact after detergent treatment, the CD41⁺ MPs contained in mpICs are detergent soluble, further establishing their phospholipid composition (Fig 3G).

**Platelet mpICs form independently of FcγRIIA**

Human platelets express the IC receptor FcγRIIA (CD32a; Huang et al., 2011; Parren et al., 1992). We thus postulated that CD32a present on platelet-derived MPs may contribute to formation of mpICs. In this set of experiments, we initially assessed CD32a expression by platelet-derived MPs. Since platelets promptly release MPs following stimulation of the collagen receptor glycoprotein VI (GPVI) (Boilard et al., 2010; Knight et al., 1999), and since GPVI deficiency in mice leads to reduction of the severity of arthritis (Boilard et al., 2010), we generated MPs via this arthritis-relevant stimulus. Here, we find that platelet-derived MPs retain CD32a (Fig 4A). Examination of MPs in RA SF demonstrates they too harbour CD32a (Fig 4B).
To assess a contribution of platelet MP CD32a in mpIC formation, we incubated in vitro generated platelet MPs in the presence of RA SF ($n = 10$) or PA SF ($n = 18$). In this assay, the fluorescent label present in in vitro MPs affords discrimination of newly formed mpICs from those present endogenously. As anticipated, the fluorescent platelet MPs are easily detected by hs-FCM, are smaller than intact platelets, the vast majority of them having dimensions of $100–300$ nm in diameter (Fig 4C).

Strikingly, the incubation of fluorescent platelet MPs in RA SF yields two subpopulations (Fig 4D), including the larger dimension ($700–3000$ nm) subpopulation that contains mpICs (Fig 4E). Interestingly, this subpopulation does not form when the platelet MPs are exposed to PA SF (Fig 4D, F and G). To explore the contribution of CD32a in formation of mpICs in RA SF, we pre-incubated the platelet MPs with a blocking CD32a antibody. We find that blockade of CD32a does not impede formation of mpIC (Fig 4G; $n = 10$, $p = 0.4478$).

Role of citrullination in generation of mpICs
Autoantibody/antigen binding comprises another plausible mechanism for formation of mpIC. Among the mechanisms that occur in RA SF and not in PA SF is citrullination, a process that generates neoepitopes recognized by autoantibodies present in abundance in many patients with RA (Yoshida et al, 2006). Specifically, citrullination is a posttranslational modification of peptidyl-arginine to peptidyl-citrulline by peptidyl arginine deiminase (PAD) enzymes; in RA SF, the PAD4 isoform levels are significantly elevated (Arita et al, 2004; Lundberg et al, 2005). Given that MPs are present in a milieu where citrullination is active, we hypothesized that the MP surface proteins may become citrullinated and give rise to autoantigens recognized by autoantibodies in RA patients and thereby promote mpIC formation. Using hs-FCM, we first evaluated whether platelet MPs are citrullinated in the course of RA pathogenesis. We find that, unlike platelet MPs generated in vitro and those in PA SF, the platelet MPs in RA SF contain citrullinated epitopes (Fig 5A and B), pointing to citrullination of MPs as a potential mechanism leading to recognition by autoantibodies.

To evaluate the contribution of citrullination on MPs to recognition by autoantibodies in RA SF, we incubated platelet MPs in presence of purified PAD4 and assessed their antigenicity to IgG from RA SF. Interestingly, we find that multiple citrullinated proteins in platelet MPs are recognized by autoantibodies from RA patients (6 RA patients out of 12; 2 patients represented in Fig 5C). For comparison, we evaluated whether antibodies from PA could recognize citrullinated proteins from platelet MPs. We demonstrate that citrullination

Figure 2. Visualization of the mpICs in RA SF. Cryo-TEM detection of immunoglobulins and phosphatidylserine exposing MPs using, respectively protein A-conjugated gold nanoparticles (10 nm) and Annexin-V-conjugated gold nanoparticles (4 nm). A, B. Representative observations obtained using RA SF in which MPs (white boxes labelled MP 1 and MP 2 (A) and MP (B)) were colocalized with $2 \mu m$ diameter mpICs. White arrows indicate the edge of the IC where MPs were detected. Black arrows indicate the carbon matrix of the perforated support film used for TEM. Insets (bottom panels) include individual MPs. Immunoglobulins detected using protein A conjugated nanospheres (10 nm) are indicated with white arrowheads and MPs detected using Annexin-V conjugated nanospheres (4 nm) are indicated by black arrowheads. Note that some MPs were Annexin-V negative.
C. Relatively smaller mpICs were also visualized. White and black arrowheads indicate immunoglobulins and phosphatidylserine, respectively. Scale bars are presented under each panel.
of MPs does not increase binding of antibodies from SF of PA patients (0 PA patient out of 8 tested; 2 patients represented in Fig 5D), consistent with the minimal presence of mpICs in this disease (Fig 3B and F).

Identification of the autoantibodies derived from mpICs
Proteomic analyses permit the identification of the antigens targeted by autoantibodies (Hueber et al, 2005; Monach et al, 2009; Zhao et al, 2008). To identify autoantigens expressed by platelet MPs, we isolated the CD41\(^{+}\) mpICs from RA SF using magnetic affinity columns. These CD41\(^{+}\)-enriched preparations, composed of immunoglobulins and complement C3a (466.6 ± 193 pg C3a/μg protein, \(n = 23\)), were applied to protein G affinity columns and the IgG within mpICs were eluted. Using an autoantigen microarray (Hueber et al, 2005; Robinson et al, 2002), we demonstrate that the IgG from platelet mpICs associate with a broad series of recognized citrullinated autoantigens (Fig 6A).

MPs exhibit autoantigens
Having identified the autoantibodies in platelet mpICs, we next used mass spectrometry to determine whether platelet mpICs also include autoantigens. We demonstrate that several canonical RA autoantigens are present in platelet mpICs (Table 1). Among these autoantigens present in platelet mpICs and recognized by the IgG eluted from platelet mpICs, we focused our attention...
Figure 4. Platelet MPs form mpICs independently of CD32a.

A,B. The expression of CD32a by platelet MPs was determined by hs-FCM and Western blot analysis (inset in A). The platelet MPs were generated in vitro upon platelet GPVI stimulation (A) and the endogenous MPs in RA SF were detected using Annexin-V (B). Blue: isotype; grey: specific CD32a labeling (n = 3).

C. FSC-PMT and SSC profiles of the fluorescent platelets (top panel) and platelet MPs (bottom panel) (n = 10). The relative dimensions are presented according to size-defined microsphere calibrations.

D–G. Results obtained following the incubation of exogenous fluorescent platelet MPs in RA and PA SF (n = 10 RA and n = 18 PA). (D) Representative FSC-PMT and SSC plots obtained using RA (top) and PA SF (bottom). Two subpopulations (subpop 1 and 2) were detected in RA and only one in PA SF (1). (E,F) hs-FCM evaluation of the presence of IgG on surface of MPs upon incubation in RA (E) and PA SF (F) using Cy5-conjugated anti-IgG antibody. The four-quadrant gates were positioned according to the isotypic controls. (E) MPs (in green) are IgG− and show dimensions ranging from 100 to 300 nm (lower inset) while the mpICs (in blue) have dimensions ranging from 700 to 3000 nm (upper inset). (D,E) The relative dimensions are presented according to size-defined microsphere calibrations. (G) hs-FCM quantifications of the mpICs were determined in absence (1st and 3rd column) or presence (2nd column) of CD32a blocking antibody (1st and 2nd column p = 0.4478 (unpaired t-test), 1st and 3rd column **p < 0.0001). Statistical analyses are presented under the graphs. Data are mean ± SEM.
on the two previously described autoantigens vimentin (El-Gabalawy & Wilkins, 2004; Kurki et al, 1983) and fibrinogen (Takizawa et al, 2006). Vimentin is an intracellular cytoskeleton protein expressed on the surface of platelet-derived MPs (Podor et al, 2002) and autoantibodies directed against citrullinated-vimentin are present in RA SF (El-Gabalawy & Wilkins, 2004; Kurki et al, 1983). We thus examined the expression of vimentin on surface of in vitro generated platelet MPs and platelet MPs contained in RA SF. We find that the surface of both in vitro generated platelet MPs and those isolated from RA SF exhibit significant expression of vimentin (Fig 6B).

Fibrinogen is also a known autoantigen in RA and autoantibodies directed against citrullinated fibrinogen suffice to induce arthritis in mice (Ho et al, 2010). While fibrinogen is a ligand of the platelet integrins GPIIb/IIIa (Bodary et al, 1989), we confirmed that fibrinogen interacts with platelet MPs. We therefore examined the ability of platelet MPs to associate with fluorescent fibrinogen using hs-FCM. Interestingly, exogenous fibrinogen promptly binds to platelet MPs obtained in vitro and to platelet MPs from RA SF, demonstrating that MPs of platelet origin associate with the autoantigen (Fig 6C). Fibrinogen is expressed in the platelet’s alpha granules.
(Sehgal & Storrie, 2007), is present in RA SF (Takizawa et al, 2006) as well as being an abundant plasma protein. We thus evaluated whether platelet MPs interacted with endogenous fibrinogen in vitro and ex vivo. Interestingly, we demonstrate that, similar to platelet MPs produced in vitro, platelet MPs present in RA SF exhibit surface fibrinogen (Fig 6D). Together, these data show that platelet MPs are capable of displaying autoantigens vimentin and fibrinogen which, when citrullinated, could allow binding by autoantibodies in RA SF.

Platelet mplICs are pro-inflammatory

The inflammatory lipid mediators leukotrienes are present in RA synovial fluid (Klickstein et al, 1980) and its production by neutrophils, a cellular lineage dominant in the synovial fluid from RA patients (Edwards & Hallett, 1997), contribute to the pathophysiology of inflammatory arthritis in in vivo mechanistic models (Chen et al, 2006). Similarly to MPs, the mplICs can be centrifuged and used as cellular stimulus. We thus centrifuged SF from RA patients and used the resulting pellet to determine its potency on human neutrophils. We demonstrate that this fraction, which contains both MPs and mplICs, can stimulate neutrophils to produce leukotrienes (Fig 7A). We next used in vitro generated mplICs to examine whether they could elicit the release of leukotrienes from neutrophils. We find that mplICs, which spontaneously form after the co-incubation of platelet MPs with anti-fibrinogen (Fig 7B), induce robust leukotriene production by neutrophils (Fig 7C). For comparison, platelet MPs and anti-fibrinogen are only modestly active when added to neutrophils separately (Fig 7C). To assess the relative pro-inflammatory activity of mplICs, we fractionated mplICs, MPs and anti-fibrinogen ICs via size exclusion filtration (800 nm pores). Interestingly, we show that the mplIC depletion abrogates much of the leukotriene stimulation in this assay (Fig 7C), establishing that the platelet mplICs are active and highly pro-inflammatory.
DISCUSSION

Our work identifies a highly pro-inflammatory macromolecular structure composed of MPs and immune complexes abundant in RA synovial fluid. Further, our mechanistic studies show that MPs, including platelet MPs, in RA SF are not naked phospholipid vesicles. Rather, they express or associate with autoantigens, can be citrullinated and form bioactive inflammatory mpICs.

The identification of MPs as a site of autoantigen expression extends previous seminal observations regarding MPs and ICs in RA synovial fluid. Others had suggested that complement and immunoglobulins were associated with the substantial majority of MPs in RA SF (Biro et al., 2007). However, no membrane markers such as Annexin-V, or lineage markers such as CD41, were utilized to distinguish MPs from ICs in those standard flow cytometry experiments. More recent demonstration of common biophysical properties (size, light scattering, sedimentation) between ICs and MPs has called into question whether or not MPs and immunoglobulins are associated in RA SF and demonstrate the need for using lineage markers or other methods to further clarify the interpretation of previous observations (Gyorgy et al., 2011a). Our findings refine and unify these discrepant observations by demonstrating that although only a proportion (~7%) of the MPs are part of mpICs, the majority of the detectable ICs are in fact mpICs.

The presence of immunoglobulins on surface of MPs in blood during RA has been previously examined (Nielsen et al., 2012; van Eijk et al., 2010). In contrast to our demonstration of MP interactions with ICs in RA SF, those studies did not find evidence of MP association with ICs in RA blood. Although these observations may point to the existence of highly potent vascular and reticular-endothelial system clearance mecha-
nisms, this may also suggest that the mplICs form locally, inside the inflamed joint. Indeed, the MPs derived by platelets in blood during RA (Knijff-Dutmer et al, 2002; Sellam et al, 2009) may accumulate in the SF through the gaps present between the endothelial cells in the inflamed vasculature (Boilard et al, 2012; Cloutier et al, 2012). Once in SF (where PAD4 is present), MPs may undergo citrullination and form mplICs. The exact anatomical site where mplICs form and the mechanism(s) of transportation of mplICs remains the subject of intense investigation.

Although the detection of phosphatidylserine is commonly used to determine the presence of MPs, Annexin-V MP+ MPs are also observed in substantial numbers associated with ICs. Nevertheless, all the mplICs we examined by cryo-TEM were composed of at least one Annexin-V MP+, suggesting that quantifications of mplICs based on Annexin-V detection still remain reasonably accurate. Although little is known about the origin of these Annexin-V MP+ MPs, they are also abundant in plasma (Connor et al, 2010) and may originate from distinct stimuli. Indeed, platelet activation via collagen or thrombin produces Annexin-V MP+ MPs (Connor et al, 2010; Perez-Pujol et al, 2007). Their presence provides evidence for further significant diversity of MPs in RA SF.

While platelet-derived MPs do express CD32a, its contribution to formation of mplICs is quantitatively modest. On the other hand, we show that platelet MPs can interact with autoantibodies against citrullinated antigens via at least two mechanisms. (i) following the citrullination of its surface and (ii) upon binding to citrullinated proteins. Autoantigens other than vimentin and fibrinogen may also be expressed on surface of platelet MPs during RA. Indeed, multiple citrullinated proteins derived from PAD4-treated MPs are recognized by RA autoantibodies. Further, we also identify autoantibodies against canonical citrullinated RA autoantigens such as filaggrin (including cfc), enolase and histone H2A/a in mplICs. Among these other proteins, only histones were also identified in our mass spectrometry analyses. Histones may be associated with DNA, itself bound to MPs. Alternatively, histones are recognized potent platelet stimuli and can associate with platelets directly (Fuchs et al, 2011). Platelet MPs, like platelets, may thus interact with histones and could be recognized by anti-histone autoantibodies. Although the contribution of these autoantigens to mplIC formation remains to be identified, we establish that major autoantigens in RA are exposed on the surface of platelet-derived MPs.

Other types of extracellular vesicles may express autoantigens. Small apoptotic CD3+ T cells, for instance, expose vimentin (Boilard et al, 2003) and could potentially interact with anti-vimentin autoantibodies if present in RA SF. Furthermore, exosomes, vesicles derived from intracellular compartments, also display antigens in RA SF (Skriner et al, 2006). MPs from other cellular origins (other than platelet-derived) may also express autoantigens. Considering that MPs from multiple sources populate the SF (Berkmans et al, 2002; Boilard et al, 2010), it is highly plausible that they too form mplICs. We revealed the capability of PAD4 to use platelet MPs as substrate. This process is likely to occur on other MPs, regardless of their origin, promoting the formation of additional citrullinated autoantigens in RA SF. However their identity and contribution remain to be established.

Recognizing the pro-inflammatory functions of MPs (Berkmans et al, 2005; Boilard et al, 2010; Distler & Distler, 2010; Distler et al, 2005a; Messer et al, 2009; Reich et al, 2011) and IC (Ho et al, 2010; Korganow et al, 1999; Kuhn et al, 2006; Stuart & Dixon, 1983) when taken separately, our identification of mplICs in synovial fluid uncovers a previously unappreciated physiology of potential relevance both to host defense and to autoimmune disease. During infections, ICs can efficiently trigger the opsonization and the clearance of pathogens. Platelets are highly potent producers of MPs and there is a growing appreciation of the role of platelets in immunity (Boilard et al, 2012; Semple et al, 2011). Although the recognition of bacterial products by platelets can initiate the production of MPs (Brown & McIntyre, 2011), whether the formation of inflammatory mplICs can occur in a physiologically beneficial manner in the course of the responses against pathogens is unknown.

In the context of autoimmunity, we show that platelet MPs can support immunoglobulin deposition. Since platelet MPs are abundant in autoimmune diseases (Berkmans et al, 2005; Boilard et al, 2010; Distler & Distler, 2010; Distler et al, 2005a; Messer et al, 2009; Reich et al, 2011), they may be a crucial source of autoantigens for the constant autoantibody deposition that perpetuates inflammation in chronic disorders. We further demonstrate that platelet mplICs are highly potent in promoting the production of leukotrienes by neutrophils. In addition to their capability to activate leukocytes, mplICs may harbour unique roles, not played by conventional ICs. Although we do not exclude that MPs also nucleate ICs, our analyses permitted us to visualize MPs at the periphery of the ICs. An inflammatory mplIC may thus interact with different cell types or may be directed to specific locations via the adhesion molecules present on the MPs that populate its surface. Further, we speculate that the formation of mplICs contributes to disease pathophysiology in other disorders. ICs are also present in multiple inflammatory autoimmune disorders and are reported to propagate disease (Cross et al, 2001; Ho et al, 2010; Korganow et al, 1999; Kuhn et al, 2006; Monach et al, 2009; Munoz et al, 2010; Ruiz-Rastorza et al, 2010; Stuart & Dixon, 1983; Voulgaris & Tzioufas, 2010; Zhao et al, 2008; Ziemssen & Ziemssen, 2005).

Indeed, circulating MPs in SLE patients are associated with autoantibodies and complement (Nielsen et al, 2012; Ullal et al, 2011). In sum, the mechanism behind the creation of functional mplICs, presented here, may well apply to other biological contexts.

In conclusion, we report that in RA, platelet MPs exhibit antigens that are recognized by RA specific autoantibodies. ICs are commonly described as immunoglobulins-, antigens- and complement-containing structures. We clearly establish that ICs can also contain MPs, including platelet MPs, and form pro-inflammatory mplICs. These observations extend previous definitions about the nature of ICs and expand our insights into the contributions of MPs and ICs to disease physiology in RA. Considering the rapidly emerging functions of inflammatory MPs, our findings point to potential roles in diverse autoimmune diseases characterized by presence of autoantibodies and MPs.
MATERIALS AND METHODS

Collection and preparation of synovial fluids
Human knee SFs as discarded material from patients with various arthritides undergoing diagnostic by the treating attending rheumatologist or therapeutic arthrocentesis. All studies received Institutional Review Board approval (BWH). Fresh SF harvested without anticoagulant were cleared of leukocytes by centrifugation at 1900g for 30 min at 4°C, were aliquoted and were kept at –80°C.

Platelet MP production and isolation
Platelets were obtained from citrated blood of healthy human volunteers under an approved Institutional Review Board protocol (CRCHUQ, Université Laval). Platelets were isolated (Boillard et al., 2011), resuspended at 100 × 10⁹/ml in Tyrode's buffer and stimulated using 0.5 μg/ml cross-linked collagen related peptide (Kehrel et al., 1998) for 120 min at RT. The activation reaction was stopped by addition of 20 mM EDTA. The preparation was centrifuged at 1300g for 5 min twice, then at 18,000g for 90 min at 18°C and the pellet containing the MPs was resuspended in Tyrode's buffer. When fluorescent MPs were required, platelets were incubated in presence of 5 μM Cell Tracker CMFDA (5-chloromethylfluorescein diacetate, Invitrogen, ON, Canada) for 15 min prior to stimulation.

Flow cytometry analyses of MPs and pre-analytical steps
MPs contained in SF were not pelleted before labelling to ensure that most of the MPs we analysed (Lacroix et al., 2012). MPs were not filtered to ensure we analysed the larger mpICs. All of the buffers were filtered on 0.2 μm pore size membranes (Fisher Scientific, ON, Canada). A forward scatter (FSC) coupled to a photomultiplier tube (PMT) ‘small particles option’ (FSC-PMT) (rather than the usual diode; van der Vlist et al., 2012) with a 488 nm solid state, 100 mW output blue laser (rather than the conventional 20 mW), a 633 nm HeNe, 20 mW output red laser and a 405 nm solid state diode, 50 mW output violet laser were mounted on the FACS Canto II Special Order Research Product used for all our studies (BD Biosciences, ON, Canada). The chosen parameters were optimal to detect particles from 100 to 3500 nm simultaneously on the FSC-PMT.

In all experiments, the sensitivity and specificity of the MP labelling were rendered optimal by using fluorochromes excited by three distinct lasers.

Evaluation of presence of antigens on MP surface
Fluorescent platelet MPs (5 × 10⁶) or RA SF (5 μl pre-incubated with Annexin-V-V450) were incubated with 2 μl of PE-conjugated anti-human CD32 (clone IV.3) (Beckman Coulter, ON, Canada). To determine the capability of MPs to associate with exogenous fibrinogen, 15 μg/ml of Alexa Fluor-647-conjugated fibrinogen (Invitrogen) was incubated with 10 × 10⁶ platelet MPs or added to 10 μl of RA SF in a final volume of 100 μl for 48 h at 4°C. Their associations were evaluated using Cell-Tracker fluorescence (for platelet MPs) or anti-CD41-PE (for SF). To detect vimentin and fibrinogen on surface of MPs, platelet MPs (20 × 10⁶) and RA SF (20 μl) were pre-incubated with 20 μg/ml of CD32a blocking Fab fragment antibody for 15 min to abrogate any risk of potential non-specific binding of primary/secondary antibodies to platelet Fc receptor. MPs were then incubated with 25 μg/ml goat anti-fibrinogen (Abcam) or 1:100 goat anti-human vimentin (Sigma–Aldrich, ON, Canada) for 4 h at 4°C. Samples were washed, centrifuged and pellets retrieved in 100 μl of PBS. For flow cytometry detection, 6.25 μg of DyLight 649-conjugated F(ab′)₂ anti-goat IgG (Jackson Immunoresearch) and reactive proteins were visualized by chemiluminescence (Perkin Elmer, MA, USA).

MP and IC labelling
SF (10 μl) were incubated with 0.5 μg of Cy5-conjugated F(ab′)₂ goat anti-human IgG (anti- IgG-Cy5) (Jackson Immunoresearch, PA, USA) and 0.5 μg of PE-conjugated mouse anti-human CD41 (M148) (anti-CD41-PE) (Abcam, MA, USA) in combination to 5 μl of FITC or V450-conjugated Annexin-V (BD). The samples were labelled during 30 min in a volume of 100 μl of Annexin-V buffer 1× and diluted to 600 μl before hs-FCM analysis. To process the data quantitatively, 100,000 polystyrene microsphere (15 μm diameter; Polysciences, PA, USA) were added to each tube and 1000 microspheres were acquired. The included Annexin-V⁺ or CD41⁺ events were portrayed as FSC-PMT versus side scatter (SSC) graph and the relative dimensions were displayed according to the acquisition of Sky Blue microspheres of mean diameter of 90, 220, 450, 840 and 3200 nm (Spherotech, IL, USA). The sensitivity of the MPs to detergent was assessed by addition of Triton X-100 to the SF samples (1:5 in PBS) prior to addition of the antibodies (Cyorgy et al., 2011a).

IgG–MP interaction
Fluorescent MPs (20 × 10⁶) were incubated in presence of 50 μl RA or PA SF in final volume 100 μl PBS for 48 h at 4°C. Then, 50 μl of the cocktail were incubated with anti-IgG-Cy5 as described above. When the contribution of CD32a was evaluated, 20 μg/ml of CD32a blocking Fab fragment antibody (clone IV.3, gift from Dr Paul Naccache, Université Laval) was added 15 min prior to MP addition to SF.

Western blotting
Platelets and MPs were prepared as described above, lysed and the protein content was determined using the Pierce BCA protein assay kit (Fisher Scientific). One microgram of sample was lysed in Laemmli buffer, electrophoresed, transferred onto membranes and incubated in 0.2% milk/TBS-Tween solution containing a serum raised against a peptide in the cytoplasmic domain of CD32a (CT10, Ibarrola et al., 1997). The membrane was washed, treated with Peroxidase-AffiniPure anti-rabbit-IgG (Jackson Immunoresearch) and reactive proteins were visualized by chemiluminescence (Perkin Elmer, MA, USA).

In vitro citrullination
Platelet MPs were prepared as described above and citrullinated in vitro by rabbit muscle peptidyl arginine deiminase (PAD, Sigma–Aldrich). 350 × 10⁶ MPs were incubated with/without 3 U of PAD for 18 h as described (Kuhn et al., 2006). Samples were lysed in Laemmli buffer and processed as described above. The PVDF membranes were incubated 18 h in 10% of SF diluted in TBS-Tween, washed and treated with Peroxidase-AffiniPure Goat Anti-Human IgG (Jackson Immunoresearch).

IgG BioPlex
To isolate the IgG contained in CD41⁺ mpICs, RA SF (300 μl) were incubated in presence of 1.2 μg of anti-CD41-PE for 30 min, then with 50 μl anti-PE magnetic beads (Miltenyi Biotec (MACS), CA, USA) for
Immune complexes contain microparticles

The paper explained

PROBLEM:

Immune complexes (ICs) are formed after antibody deposition against antigens and propagate inflammation in autoimmune-driven autoimmune diseases. Extracellular vesicles of submicron dimensions, called microparticles, are also often present in the same pathologies where ICs are observed. Understanding how ICs continuously form is of high relevance to human diseases.

RESULTS:

We used a new generation of flow cytometer and sophisticated cryo-transmission electron microscopy approaches to characterize and quantify ICs and microparticles in the synovial fluid from patients affected with rheumatoid arthritis (RA). We identify a new class of ICs that predominates in RA; the microparticle-associated immune complexes (mpICs). We further reveal that platelet microparticles participate to the formation of mpICs via exposure of the canonical RA autoantigens. We demonstrate that these platelet mpICs are highly active, eliciting pro-inflammatory leukotriene release by neutrophils.

IMPACT:

Considering the abundance of platelet microparticles in autoimmune disease such as RA, this suggests that microparticles may serve to the constant autoantibody deposition and perpetuation of inflammation in chronic autoimmune inflammatory disorders.

Cryo-TEM and gold labelling of mpICs from RA SF

For cryo-Transmission Electron Microscopy (TEM) experiments, samples were diluted 10× in a buffer containing 150 mM NaCl, 2 mM CaCl₂, and 10 mM HEPES, pH 7.4. A 10 μl aliquot of SF was mixed with 1 μl of 10 nm Protein A-conjugated gold nanoparticles (Ted Pella, Inc.; 0.5 μg/ml final concentration), incubated for 30 min, mixed with 1 μl of 4 nm Annexin-V-conjugated gold nanoparticles suspension (1.4 × 10¹⁵ particles/ml final concentration) and further incubated for 15 min. Aliquots (4 μl) were deposited on TEM grids coated with a perforated carbon film and quickly frozen in liquid ethane. TEM grids were mounted on a Gatan 626 cryoholder and transferred into a Tecnai F20 (FEI) microscope operated at 200 kV. Images were recorded with an USC1000-SSCCD camera (Gatan). The synthesis and characterization of Annexin-V-conjugated gold nanoparticles will be presented elsewhere (patent application Mornet and Brisson WO2007122259).

Identification of autoantigens expressed by platelet MPs from RA SF

We used mass spectrometry to survey the presence of known autoantigens in platelet MPs in RA SF (see Supporting Information Table S2 for detailed list). Protein concentration from individual SF CD41⁺ MPs (isolated using MACS as described above) was measured using DC Protein Assay (Bio-Rad, Hercules, CA). Twenty-five micrograms proteins from individual SF CD41⁺ MP sample were reduced and alkylated by using 21 mM triethyl phosphine (TEP) and 58 mM iodoethanol (IE). The samples were speed dried in a high speed vacuum centrifuge and redissolved in 100 μl of 0.1 M ABC buffer containing 0.1% perfluorocarbonic acid (PFOA). Trypsin was added in the ratio of 1 μg per 50 μg of proteins. The samples were placed in a 37°C water bath for 16 h. The reaction was stopped by drying the samples and adding 70% IPA in ammonium hydroxide (50 mM) solution, pH 10. The enzyme was inactivated by reducing (TEP/acetoniitre) at 45°C for 1 h and then alkylating (iodoethanol/HCl3CN) in the dark at 45°C for 2 h. A 1:1:1 solution of ethanol, ethyl acetate and HPLC grade water with 0.1% TFA was added to the dried peptide digest and subjected to high speed vacuum centrifuge to remove PFOA. The samples were then analysed by LC–MS/MS. A total of four SF biological replicates were analysed by mass spectrometry. PFOA was purchased from TCI America (Portland, OR, USA). All other reagents were of the highest quality commercially available.

Mass spectrometry and data analysis

The protein digests were analysed by LC–MS/MS using an Ultimate 3000 LC system (Dionex, San Francisco, CA) interfaced to an LTQ-Orbitrap XL mass spectrometer (Thermo-Finnigan, Bremen, Germany). The platform operated in the nano-LC mode using the standard nano-ESI API stack fitted with a picotip emitter (uncoated fitting, 10 μm
samples were stored at acetonitrile (1:1) containing 12.5 ng of internal standards PGB2 and washed for 5 min with the equilibration solvent at a flow rate of 25 \( \mu l \) min, using an isocratic loading pump operated through an autosampler. After the washing step, the trapping column was switched in-line with a reversed-phase C18 Acclaim PepMap 100 column (0.075 \( \times \) 150 mm\(^2\), Dionex, Inc.) and the peptides were chromatographed using a linear gradient of acetonitrile from 4.8 to 40\% in aqueous 0.1\% formic acid over a period of 96 min at the above-mentioned flow rate such that the eluate was directly introduced to the mass spectrometer. An 80\% acetonitrile elution step was subsequently performed for 5 min prior to resetting the analytical column to the initial equilibration conditions for 11 additional minutes at the end of the chromatographic run. The mass spectrometer was operated in a data-dependent MS to MS/MS switching mode, with the five most intense ions in each MS scan subjected to MS/MS analysis. The full scan was performed at 60,000 resolution in the Orbitrap detector and the MS/MS fragmentation scans were performed in the ion trap detector (IT) CID mode such that the total scan cycle frequency was approximately 1 s. The threshold intensity for the MS/MS trigger was always set at 1,000 and the fragmentation was carried out using the CID mode using normalized collision energy (NCE) of 35. The data was collected in the profile mode for the full scan and centroid mode for the MS/MS scans. The dynamic exclusion function for previously selected precursor ions was enabled during the analysis such that the following parameters were applied: repeat count of 2, repeat duration of 45 s, exclusion duration of 60 s and exclusion list size of 150. Xcalibur software (version 2.0.7), Thermo-Finnigan, Inc., San Jose, CA) was used for instrument control, data acquisition, and data processing. MS raw data files were searched against Swiss-Prot (version 57) database using Mascot database search software (version 2.1.04, Matrix Science, London, UK) to identify peptides/proteins with the following parameters: S-hydroxyethylation of cysteine as a fixed modification, and oxidation of methionine to methionine sulfoxide as variable modifications. The search software (version 2.1.04, Matrix Science, London, UK) was used to identify peptides/proteins with the following parameters: S-hydroxyethylation of cysteine as a fixed modification, and oxidation of methionine to methionine sulfoxide as variable modifications. The mass tolerance for the precursor ion was set to 10 ppm, and for the fragment ion to 0.8 Da. Strict trypsin specificity was applied, allowing for one missed cleavage. Peptides with a minimum score of 20 were considered as significant.

Isolation and stimulation of neutrophil and leukotriene biosynthesis

Human neutrophils isolation and leukotriene quantifications were determined as described (Boyum, 1968; Flamand et al, 2002). Neutrophils were incubated at 37°C for 30 min in presence of RA SF mPCs, platelet MPs (1 \( \times \) 10\(^8\) MPs/ml), anti-fibrinogen (50 \( \mu g/ml\)), or in vitro mPCs. RA SF mPCs were enriched by centrifugations of 100 \( \mu l \) of RA SF (18,000 g for 90 min at 18°C) and resuspended in 10 \( \mu l \) of PBS. In vitro mPCs were generated by pre-incubation of MPs (1 \( \times \) 10\(^5\)/ml) and goat anti-fibrinogen from Abcam (50 \( \mu g/ml\)) at RT for 30 min. Reactions were stopped by addition of 400 \( \mu l \) cold methanol/acetone (1:1) containing 12.5 ng of internal standards PGB2 and 19-OH-PGB2. Samples were stored at –20°C O/N then analysed by reverse-phase HPLC as previously described (Borgeat et al, 1990).

Statistical analysis

Statistical significance was determined using non-parametric Mann-Whitney test. When indicated, unpaired Student’s \( t \)-test was employed. All the statistical analyses were done using Prism software package 4.00 (GraphPad Software, CA, USA).

Author contributions

NC: study conception, study design, acquisition of data, analyses and interpretation of data, manuscript preparation, statistical analyses; ST: acquisition of data, analyses and interpretation of data, manuscript preparation, statistical analyses; CC: acquisition of data, manuscript preparation, statistical analyses; RSu: acquisition of data, manuscript preparation, statistical analyses; LL: acquisition of data, manuscript preparation, statistical analyses; AA: acquisition of data, analyses and interpretation of data; RSh: acquisition of data, analyses and interpretation of data; RG: interpretation of data, manuscript preparation; PAN: contributed critical reagent, analyses and interpretation of data, manuscript preparation; RWF: generated critical reagent, manuscript preparation; WHR: analyses and interpretation of data, manuscript preparation; AB: acquisition of data, analyses and interpretation of data, manuscript preparation; DML: study conception, analyses and interpretation of data, manuscript preparation; EB: study conception, study design, acquisition of data, analyses, interpretation of data, manuscript preparation.

Acknowledgements

EB, Canadian Institutes of Health Research, The Arthritis Society, The Canadian Arthritis Network, and the Fonds de Recherche en Santé du Québec; LHB is recipient of a fellowship from the Canadian Arthritis Network; RG, Orthopaedic Research and Education Foundation; PAN, Cogan Family Foundation; RWF, British Heart Foundation; DML, NIH PO1 AI065858, Arthritis Foundation Investigator Award and the Cogan Family Foundation. We are grateful to Tania Lévesque for her technical expertise.

Supporting Information is available at EMBO Molecular Medicine online.

The authors declare that they have no conflict of interest.

References

Arita K, Hashimoto H, Shimizu T, Nakashima K, Yamada M, Sato M (2004) Structural basis for Ca(2\(+\))-induced activation of human PAD4. Nat Struct Mol Biol 11: 777-783
Berckmans RJ, Nieuwland R, Kraan MC, Schaap MC, Pots D, Smeets TJ, Sturk A, Tak PP (2005) Synovial microparticles from arthritic patients modulate chemokine and cytokine release by synoviocytes. Arthritis Res Ther 7: R536-R544
Berckmans RJ, Nieuwland R, Tak PP, Boing AN, Romijn FP, Kraan MC, Breedveld FC, Hack CE, Sturk A (2002) Cell-derived microparticles in synovial fluid
from inflamed arthritic joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis Rheum 46: 2857-2866

Beyer C, Pisetsky DS (2010) The role of microparticles in the pathogenesis of rheumatic diseases. Nat Rev Rheumatol 6: 21-29

Biro E, Nieuwland R, Tak PP, Pronk LM, Schaap MC, Sturk A, Hack CE (2007) Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals. Ann Rheum Dis 66: 1085-1092

Bodary SC, Napier MA, McLean JW (1989) Expression of recombinant platelet glycoprotein IIb/IIIa results in a functional fibrinogen-binding complex. J Biol Chem 264: 18859-18862

Boillard E, Blanco P, Nigrovic PA (2012) Platelets: active players in the pathogenesis of arthritis and SLE. Nat Rev Rheumatol 8: 534-542

Boillard E, Bourgoin SG, Bernatchez C, Surette ME (2003) Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory factor IIA phospholipase A2. Blood 102: 2901-2909

Boillard E, Larabee K, Shnayder R, Jacobs K, Farndale RW, Ware J, Lee DM (2011) Platelets participate in synovitis via Cox-1-dependent synthesis of prostacyclin independently of microparticle generation. J Immunol 186: 4361-4366

Boillard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, Massarotti EM, Remold-O'Donnell E, Farndale RW, Ware J, et al (2010) Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 327: 580-583

Borgeat P, Picard S, Vallerand P, Bourgon S, Oedeart A, Sirois P, Poubelle PE (1990) Automated on-line extraction and profiling of lipoxygenase products of arachidonic acid by high-performance liquid chromatography. Methods Enzymol 187: 98-116

Boyum A (1968) Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl 97: 77-89

Brown GT, McIntyre TM (2011) Lipopolysaccharide signaling without a role of neutrophils in rheumatoid arthritis. Arthritis Rheum 52: 2892-2897

Cloutier N, Pare A, Farndale RW, Schumacher HR, Nigrovic PA, Lacroix S, Boillard E (2012) Platelets can enhance vascular permeability. Blood 118: 3708-3714

Connor DE, Exner T, Ma DD, Joseph JE (2010) The majority of circulating microparticles fail to bind annexin V, lack phospholipid-interactive domain of collagen, whereas CD36, glycoprotein IIb/IIIa, and receptor for platelet activation: it recognizes the platelet-activating glycoprotein Ib. J Biol Chem 166: 189-197

Chargaff E, West R (1946) The biological significance of the thromboplastic protein of blood. J Biol Chem 166: 189-197

Cloutier N, Pare A, Farndale RW, Schumacher HR, Nigrovic PA, Lacroix S, Boillard E (2012) Platelets can enhance vascular permeability. Blood 118: 3708-3714

Connor DE, Exner T, Ma DD, Joseph JE (2010) The majority of circulating microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost 103: 1044-1052

Cross AH, Trotter JL, Lyons J (2001) B cells and antibodies in CNS demyelinating disease. J Neuroimmunol 112: 1-14

Distler JH, Distler O (2010) Inflammation: microparticles and their roles in inflammatory arthritides. Nat Rev Rheumatol 6: 385-386

Distler JH, Jungel A, Huber LC, Seemayer CA, Reich CF, III, Gay S, Michel BA, Fontana A, Gay S, Pisetsky DS, et al (2005a) The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. Proc Natl Acad Sci USA 102: 2892-2897

Distler JH, Pisetsky DS, Huber LC, Kalden JR, Gay S, Distler O (2005b) Microparticles as regulators of inflammation: novel players of cellular crosstalk in the rheumatic diseases. Arthritis Rheum 52: 3337-3348

Edwards SW, Hallett MB (1997) Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol Today 18: 320-324

Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 95: 14863-14868

El-Gabalawy HS, Wilkins JA (2004) Anti-Sa antibodies: prognostic and pathogenetic significance to rheumatoid arthritis. Arthritis Res Ther 6: 86-89

Flamand N, Surette ME, Picard S, Bourgon S, Borgeat P (2002) Cyclic AMP-mediated inhibition of 5-lipoxygenase translocation and leukotriene biosynthesis in human neutrophils. Mol Pharmacol 62: 250-256

Fuchs TA, Bhandari AA, Wagner DD (2011) Histones induce rapid and profound thrombocytopenia in mice. Blood 118: 3708-3714

Gyorgy B, Modos K, Pallinger E, Paloczi K, Pasztol M, Miskij P, Deli MA, Sipos A, Szalai A, Voszka I, et al (2011a) Detection and isolation of cell-derived microparticles are compromised by protein complexes resulting from shared biophysical parameters. Blood 117: e39-e48

Gyorgy B, Szabo TG, Pasztol M, Pal Z, Miskij P, Aradi B, Laszlo V, Pallinger E, Pap E, Kitel A, et al (2011b) Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 68: 2667-2688

Ho PP, Lee LY, Zhao X, Tomoka BH, Paniagua RT, Sharpe O, BenBarak MJ, Chandra PE, Hueber W, Steinman L, et al (2010) Autoimmunity against fibrinogen mediates inflammatory arthritis in mice. J Immunol 184: 379-390

Huang YZ, Chien P, Indlik ZK, Schreiber AD (2011) Human platelet FcgammaRIIA and phagocytes in immune-complex clearance. Mol Immunol 48: 691-696

Hueber W, Kidd BA, Tomoka BH, Lee BJ, Bruce B, Fries JF, Sonderstrup G, Monach P, Drijfhouw JT, van Venrooij WJ, et al (2005) Antigen microarray profiling of autoantibodies in rheumatoid arthritis. Arthritis Rheum 52: 2645-2655

Ibarrola I, Vossebeld PJ, Homburg CH, Thelen M, Roos D, Verteonhoen AJ (1997). Influence of tyrosine phosphorylation on protein interaction with FcgammaRIIA. Biochem Biophys Acta 1357: 348-345

Jy W, Tiede M, Bidot CJ, Horstan LL, Jimenez JJ, Chirinos J, AHN YS (2007) Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies. Thromb Res 121: 315-325

Kehrel B, Wierwille S, Clemenston KJ, Anders O, Steiner M, Knight CG, Farndale RW, Okuma M, Barnes MJ (1998) Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood 91: 491-499

Klockstein LB, Shapleigh C, Goetzl EJ (1980) Lipooxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritides. J Clin Invest 66: 1166-1170

Kurki P, Helve T, Virtanen I (1983) Antibodies to cytoplasmic intermediate in experimental autoimmune arthritis. J Rheumatol 10: 558-562

Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robins WH, Holers VM (2002) Elevated levels of platelet microparticles are associated with disease activity in rheumatoid arthritis. Arthritis Rheum 46: 1498-1503

Korganow AS, Ji H, Mangialaio S, Duchatelie V, Pelanda R, Martin T, Degott C, Kikutani H, Rajewsky K, Pasquali JL, et al (1999) From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10: 451-461

Kuhn KA, Kulik L, Tomoka B, Braschler KJ, Arend WP, Robinson WH, Holers VM (2006) Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 116: 961-973

Kurki P, Helve T, Virtanen I (1983) Antibodies to cytoplasmic intermediate filaments in rheumatic diseases. J Rheumatol 10: 558-562

Kuo NY, Fudenberg HH, Kuo YJ, Liao FY, Chang CH, Wang YC, et al (2006) Blood platelet microparticles in rheumatoid arthritis. J Thromb Haemost 10: 437-447

Lundberg K, Nijenhuis S, Vossenaar ER, Palmblad K, van Venrooij WJ, Klareskog L, Nienhuis S, Vossenaar ER, Palmblad K, van Venrooij WJ, Klareskog L, Zdenman AJ, Harris HE (2005) Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther 7: R458-R467
Messer L, Alsaeah G, Freyssinet JM, Zobairi F, Leray I, Gottenberg JE, Sibilia J, Tots-Orfanoudakis F, Wachsmann D (2009) Microparticle-induced release of B-lymphocyte regulators by rheumatoid synoviocytes. Arthritis Res Ther 11: R40

Monach PA, Hueber W, Kessler B, Tomooka BH, BenBarak M, Simmons BP, Wright J, Thornhill TS, Monestier M, Ploegh H, et al (2009) A broad screen for targets of immune complexes decorating arthritic joints highlights deposition of nucleosomes in rheumatoid arthritis. Proc Natl Acad Sci USA 106: 15867-15872

Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M (2010) The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 6: 280-289

Nielsen CT, Ostergaard O, Iversen LV, Truedsson L, Gullstrand B, Messer L, Alsaleh G, Freyssinet JM, Zobairi F, Leray I, Gottenberg JE, Sibilia J, Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M (2010) The role of autoantibodies and complement activation. Arthritis Rheum 64: 1227-1236

Nigrovic PA, Lee DM (2006) Innate immunity and immune complexes in rheumatoid arthritis. In Rheumatoid Arthritis, Firestein GS, Panayi G, Wollheim K (eds), pp 135-155. New York, NY: Oxford University Press

Parren PW, Warmerdam PA, Boeije LC, Arts J, Westerdaal NA, Vlug A, Capel PJ, Pereira J, Alfaro G, Goycoolea M, Quiroga T, Ocqueteau M, Massardo L, Perez C, Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean EJ, Fournel Reich N, Beyer C, Gelse K, Akhmetshina A, Dees C, Zwerina J, Schett G, Distler O, Aarden LA, van de Winkel JG (1992) On the interaction of IgG subclasses with the low affinity Fc gamma RII (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J Clin Invest 90: 1537-1546

Podor Tj, Singh D, Chindemi P, Foulon DM, McKelvie R, Weitz JI, Austin R, Ruiz-Ortiz M, Boros JM, Ploegh H, et al (2002) Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem 277: 7529-7539

Reich N, Beyer C, Gelse K, Akhmetshina A, Dees C, Zwerina J, Schett G, Distler O, Distler JH (2011) Microparticles stimulate angiogenesis by inducing ELR(+)

CXC-chemokines in synovial fibroblasts. J Cell Mol Med 15: 756-762

Robinson WH, DiGennaro C, Hueber W, Haab BB, Kamachi M, Dean Ej, Fournel S, Fong D, Genovese MC, de Vegvar HE, et al (2002) Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med 8: 295-301

Ruiz-trastorza G, Crowther M, Branch W, Khamashta MA (2010) Antiphospholipid syndrome. Lancet 376: 1498-1509

Selami J, Proulle V, Jungel A, Itah M, Miceli Richard C, Gottenberg JE, Toti F, Benessiano J, Gay S, Freyssinet JM, et al (2009) Increased levels of circulating microparticles in primary Sjogren’s syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity. Arthritis Res Ther 11: R156

Semple JW, Italiano JE, Freedman J (2011) Platelets and the immune continuum. Nat Rev Immunol 11: 264-274

Sheremata WA, Wy W, Horstman LL, Ahn YS, Alexander JS, Minagar A (2008) Evidence of platelet activation in multiple sclerosis. J Neuroinflammation 5: 27

Skinner K, Adolph K, Jungblut PR, Burnmeter GR (2006) Association of citrullinated proteins with synovial exosomes. Arthritis Rheum 54: 3809-3814

Toti-Orfanoudakis F, Wachsmann D (2009) Microparticle-induced release of nucleosomes in rheumatoid arthritis and relation with disease activity. J Thromb Haemost 5: 2009-2016

van der Vlist EJ, Nolte-'t Hoen EN, Stoorvogel W, Arkesteijn GJ, Wauben MH (2012) Fluorescent labeling of nano-sized vesicles released by cells and subsequent quantitative and qualitative analysis by high-resolution flow cytometry. Nat Protoc 7: 1311-1326

Voulgarelis M, Tzioufas AG (2010) Pathogenetic mechanisms in the initiation and perpetuation of Sjogren’s syndrome. Nat Rev Rheumatol 6: 529-537

Wolf P (1967) The nature and significance of platelet products in human plasma. Br J Haematol 13: 269-288

Yoshida M, Tsuji M, Kurosaka D, Yasuda J, Ito Y, Nishizawa T, Yamada A (2006) Evidence of platelet activation in multiple sclerosis. J Neuroinflammation 5: 527

Ziemssen T, Ziemssen F (2005) The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Autoimmun Rev 4: 460-467

EMBO Mol Med (2013) 5, 235–249

© 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.